While follicular lymphoma (FL) is exquisitely responsive to immuno-chemotherapy, many patients follow a relapsing remitting clinical course driven in part by a common precursor cell (CPC) population. Advances in next generation sequencing have provided valuable insights into the genetic landscape of FL and its clonal evolution in response to therapy, implicating perturbations of epigenetic regulators as a hallmark of the disease. Recurrent mutations of histone modifiers KMT2D, CREBBP, EP300, EZH2, ARIDIA, and linker histones are likely early events arising in the CPC pool, rendering epigenetic based therapies conceptually attractive for treatment of indolent and transformed FL. This review provides a synopsis of the main epigenetic aberrations and the current efforts in development and testing of epigenetic therapies in this B cell malignancy.
Introduction
Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma (NHL), accounting for over 20% of all NHL cases. The incorporation of the anti-CD20 monoclonal antibody, rituximab, into treatment regimens has led to considerable improvement in the outlook of FL patients with 5-year overall survival approaching 90%. However, many patients display a relapsing-remitting pattern, with the disease eventually becoming resistant to further therapy, representing a major area of unmet clinical need 1 . These patients include a high-risk subgroup (30% of patients) prone to transformation into a higher-grade lymphoma 2, 3 , and a poor-prognostic subgroup (20% of cases) who progresses or relapses within 2 years of receiving first line treatment 1 .
At the molecular level, 85%-90% of FL are characterized by the t(14;18) translocation, which places the anti-apoptotic proto-oncogene BCL2 under the transcriptional control of the IGH locus, leading to BCL2 overexpression [4] [5] [6] [7] . Intriguingly, however, t(14;18) alone is not sufficient for malignant transformation as it can be detected in healthy individuals who never develop the disease 8, 9 ; therefore, there has been a concerted effort to identify the additional "hits" that cooperate with t(14;18) to induce malignant transformation in GC B cells. Additionally, 10%-15% of FL cases do not harbor the t(14;18) translocation 10 , and the pathogenic mechanisms driving the development of this subset of FL remain largely unknown.
The mutational landscape of follicular lymphoma
FL originates from the germinal center (GC) within lymphoid tissues, where B cells undergo clonal expansion and extensive genetic modifications through the processes of somatic hypermutation and class switch recombination 11 . Genome-wide association studies 12 , cytogenetic analyses [13] [14] [15] [16] , gene expression, [17] [18] [19] and microRNA profiling 20, 21 have highlighted chromosomal alterations, including 1p36 and 6q losses, components of the tumor microenvironment, and association with HLA gene variants, among others 12, 22 . The most significant shift in our 45 . In a minority of cases, however, evolution through "sparse" CPCs occurs with little clonal resemblance between paired FL and tFL samples and presents different epigenetic mutations acquired independently 25, 27 , which is supported by a broad consensus in the literature through the contributions of several groups in the field.
Role of epigenetic regulatory mutations in lymphomagenesis
The . While it has long been assumed that mutations in epigenetic modifiers arise in GC, in vivo 
Mutations in epigenetic modifiers can predict patient outcomes in FL
FL patients who relapse within 2 years of receiving R-CHOP treatment present a significant clinical challenge. The follicular lymphoma international prognostic index (FLIPI) 57 is useful to predict prognosis based on clinical and basic laboratory parameters; however, FLIPI tends to overestimate high-risk patients at diagnosis 58 and cannot be used effectively to inform clinical decisions. Therefore, in recent years, there have been efforts to develop new experimental models, the first of which, m7-FLIPI, incorporates the mutational status of seven genes, including the five epigenetic modifiers EZH2, CREBBP, EP300, MEF2B, and ARID1A
34
. m7-FLIPI has been shown to be more effective at distinguishing between high-and low-risk FL patients measured by 5-year failure-free survival following first line R-CHOP, with almost half of the patients classified as highrisk by FLIPI re-classified as low-risk by m7-FLIPI. This new prognostic tool is also more accurate in predicting disease progression within 24 months, a surrogate endpoint for overall survival, and in identifying the small subset of patients who are at the highest risk of early treatment failure following first line R-CHOP. Critically, high risk patients tend to carry CREBBP or EP300 mutations, while EZH2-or MEF2B-mutant cases are associated with low risk disease and favorable outcome 34 and may benefit from less intensive R-CHOP regimens. However, it is still unclear how individual genetic lesions affect sensitivity to treatment (outcome predictors) or aggressiveness of the disease 7 (prognostic marker). Overall, the inclusion of epigenetic modifier mutations in patient risk stratification holds promise for more accurate prediction of patient outcomes following first line treatment with R-CHOP, although this needs further improvements in prospective studies before they can be translated into routine clinical practice.
Epigenetic inhibitors in follicular lymphoma therapy
Current treatment strategies for FL are based on a "one size fits all" approach that fails to take into account the specific genetic and epigenetic aberrations in different patients. Going forward, a more considered approach may be most beneficial for high risk patients who relapse within the first 2 years and the patients who transform to more aggressive lymphoma. The abundance and the co-founding role of epigenetic modifier mutations in indolent FL and tFL, together with the reversibility of epigenetic abnormalities, offer a platform to apply small molecule inhibitors that target these epigenetic aberrations in a precision medicine approach.
Targeting gain-of-function EZH2 mutations as emerging epigenetic therapies
EZH2 for patients who will benefit from EZH2i therapy remains challenging.
Based on recent studies, there is also the prospect of EZH2i as a means of eradicating cancer stem cells. This has been exemplified in chronic myeloid leukemia where leukemic stem cells, which are typically resistant to first-line tyrosine kinase inhibitors, are sensitive to EZH2i due to their abnormal EZH2 gain-of-function status 66, 67 . Therefore, it is worth testing the efficacy of EZH2i in targeting the subset of EZH2-mutant FL CPCs to prevent them repopulating subsequent disease relapses or transformation.
HDAC inhibitors may benefit high-risk follicular lymphoma patients
Loss-of-function mutations of CREBBP/EP300 leading to acetylation imbalance are associated with high-risk FL patients 34 , therefore providing a rationale for histone deacetylase inhibitors (HDACi) therapy for this patient category. A number of HDACi have been tested in cancer trials in recent years, with vorinostat, which is licensed for the treatment of advanced cutaneous T cell lymphoma 68 , being the most exhaustively tested orally bioavailable HDACi against lymphoid malignancies ( caveats limiting widespread application of epigenetic therapies. In the example of HDACi, the exact mechanism of action in patients is poorly understood, as they can exert their function by acetylating both histone and non-histone proteins that are implicated in several biological processes, including cell cycle 73 , DNA damage response, apoptosis 74, 75 , angiogenesis 76 , and regulation of tumor immunology 77 . It is important, therefore, that we include routine testing of mutations as part of existing clinical trial programs in FL and that we equally increase our efforts in understanding the functional roles of these inhibitors within the context of complex tumor genetics.
Lysine specific demethylase inhibitors: a new area of epigenetic therapy
Despite >80% of FL cases carry KMT2D mutations 24, 25, 36 , no attempt has been made to target the resulting epigenetic abnormalities. 24, 26 . One therapeutic strategy may be to inhibit lysine demethylases (KDMs) that regulate H3K4 methylation, in order to counteract the H3K4 methylation imbalance in loss-of-function KMT2D mutants. The KDM family consists of seven subfamilies, with the KDM1 and KDM5 families both able to regulate H3K4 methylation. A number of inhibitors of these two families have been reported, although neither family has been investigated in lymphoma.
Several inhibitors of the KDM1 family member LSD1 are currently undergoing clinical trials for other malignancies, such as acute myeloid leukemia (TCP
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, ORY-1001, 79 and GSK2879552
80
). More recently, three potent KDM5 inhibitors (EPT-103182 81, 82 , CPI-455, 83 and KDM5-C70 84 ) have been reported in pre-clinical studies, all of which demonstrate selectivity over other KDM families, increase H3K4me3 levels and cause significant inhibition of cell proliferation in myeloma 84 and drug-resistant small cell lung cancer 83 . There is value, therefore, in exploring LSD1 and KDM5
inhibitors as a means of potentiating a new area of epigenetic therapeutics for KMT2D-mutant FL.
Conclusion
The landscape of FL demonstrates a complex pattern of frequent mutations in epigenetic modifiers that are co-founding events arising in the CPC and remain stable during disease progression and transformation, providing a compelling rationale for using epigenetic therapies.
These aberrant epigenetic mechanisms have also been implicated in predicting patient outcomes as demonstrated by the m7-FLIPI model, which links 7 mutations, 5 of which with epigenetic function, to FL prognosis. While promising, it is yet to be determined whether these mutations can be used to robustly stratify patients at diagnosis to inform clinical decision making, and whether they have any predictive value in determining response to epigenetic therapy in particular.
Collectively, our understanding of abnormal epigenetic mechanisms in FL is still at its infancy , CREBBP [25] [26] [27] 34 , EP300 26, 27, 32, 34 , linker histone H1 and histone H2 family 25, 27, 32 , SWI/SNF complex members (ARID1A, ARID1B, BCL7A) 27, 32, 34 , and MEF2B 23, 25, 32, 34 depicted above. Mutations in epigenetic modifiers occur concurrently in majority of FL patients and mechanistically it is not clear whether they act alone or cooperatively in driving B cell malignancy.
H3Kac, histone H3 lysine acetylation; H3K4me3, histone H3 lysine 4 trimethylation; H3K27me3, histone H3 lysine 27 trimethylation.
